Please assess the completion status of the following clinical trial:

Trial Title: DLBS1033 for the Treatment of Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with age of 18-75 years .~* Has been diagnosed with acute ischemic stroke clinically confirmed by CT scan.~* Modified National Institutes of Health Stroke Scale (mNIHSS) score \>= 5.~* Patients present at hospital and receiving first dose of study medication within 72 hours after the onset of the stroke symptoms.~* Able to take oral medication.~Exclusion Criteria:~* For females of childbearing potential: pregnancy and lactation period.~* History of or current hemorrhagic stroke (within the last 3 months).~* Transient ischemic stroke (TIA).~* Patients with seizure at the onset of stroke.~* History of serious head injury within the last 3 months.~* History of major surgery within the last 3 months.~* Serious cardiovascular conditions, such as myocardial infarction, CHF grade III and IV (NYHA classification), aorta dissection, and atrial fibrillation within the last 6 months.~* Presence of severe renal or hepatic dysfunction~* Presence of acute or chronic infections.~* Thrombocytopenia (thrombocytes level \< 150.000/ul).~* Patients with higher risks of bleeding.~* Uncontrolled hypertension (systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110 mmHg).~* Random plasma glucose \>= 200 mg/dL.~* Current or regular use of oral anticoagulants, antiplatelets other than study medication, and herbal medicines.~* Hypersensitive to the investigational product(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
- DLBS1033 Group (Type: EXPERIMENTAL): DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period

Based on this trial design, predict the completion outcome and termination type (if applicable).